Navigation Links
Tianyin Promotes its Flagship Product Portfolio at the 45th 2010 National New Special Drugs Trade Fair in July at Beijing
Date:6/28/2010

CHENGDU, China, June 28 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical (NYSE Amex: TPI), a biopharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine and branded generics will exhibit and promote its flagship product portfolio at the 45th 2010 National New Special Drugs Trade Fair at Beijing National Convention Center from July 8th, till July 10th. Tianyin's portfolio is featured by the patented Ginkgo Mihuan Oral Liquid (GMOL) for cardiovascular and central nervous system indications, Apu Shuangxin (APU, Benorylate Granules) for fever, inflammation and rheumatism, Xuelian Chongcao Oral Solution (XLCC) for heart diseases, asthma and gynecological conditions, along with other prescription medicines that target high incidence China health care indications.

"Years of sales and marketing efforts by Tianyin Pharmaceutical have established a nationwide network that covers more than 850 hospitals with an in-depth market penetration," said Dr. Jiang, Guoqing. "The network synergizes with our marketing strategies that target high incidence, chronic conditions in a growing aging Chinese population whose health care spending is boosted by an increasing disposable income and health care funding by the government. This synergy is centered on our flagship portfolio such as GMOL, APU, and XLCC etc. that contributes close to 50% of our annual revenue."

About National New Special Drugs Trade Fair

http://www.newdrugschina.com/

The 45th National New Special Drugs Trade Fair gathers the leading pharmaceutical enterprises, elite new drug R&D institutes, the technology transfer organizations, and the biomedical science and technology industrial areas in China to offer a platform for both scientific and commercial collaboration and development. An International new medicine technology transfer and the commercialization collaboration summit will be conducted with the main Trade Fair.

About Tianyin Pharmaceutical

Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, Sichuan Province of China, is a leading biopharmaceutical company that specializes in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and branded generics. Tianyin is equipped with two state-of- the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. Tianyin currently manufactures and markets a comprehensive portfolio of 56 products, of which 23 are listed in the highly selective National Medicine Catalog of the National Medical Insurance program, 7 are included in the essential drug list of China. Tianyin has an extensive nationwide distribution network with a sales force of 720 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

     Tianyin Pharmaceutical Co., Inc.
     James Jiayuan Tong M.D. Ph.D.
     Chief Financial Officer, Chief Business & Development Officer
     Director
     23rd Floor Unionsun Yangkuo Plaza
     No. 2, Block 3, South Renmin Road
     Chengdu, 610041
     China
     Web:   http://www.tianyinpharma.com
     Email: Dr.Tong@tianyinpharma.com
     Tel:   +86-28-8551-6696 (Chengdu, China)
            +86-134-3655-0011
            +1-949-350-6999 (U.S.)


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tianyin Pharmaceutical Co., Inc. to Host Third Fiscal Quarter 2010 Results Earnings Conference Call on Wednesday, May 12, 2010 at 9:00 a.m. ET
2. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
3. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
4. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
5. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
6. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
7. Parata Promotes Sales and Engineering Executives
8. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
9. Cappella Promotes Sideguard & Serial IVUS Analysis at JIM 2010
10. PLAN C Agency Promotes Hepatitis B Awareness Through B HERE
11. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):